U.S. News & World Report Names Jupiter Medical Center a High Performing Hospital for Stroke, Colon Cancer Surgery, Lung Cancer Surgery, Kidney Failure and COPD

U.S. News & World Report, the trusted source in hospital rankings and consumer advice, has named Jupiter Medical Center a 2022-2023 High Performing hospital for Stroke, Colon Cancer Surgery, Lung Cancer Surgery, Kidney Failure and COPD. This is the highest award a hospital can earn for U.S. News’ Best Hospitals Procedures & Conditions ratings.

The annual Procedures & Conditions ratings are designed to assist patients and their doctors in making informed decisions about where to receive care for challenging health conditions or elective procedures.

“The recognition from U.S. News & World Report is a tremendous accomplishment for Jupiter Medical Center,” says Amit Rastogi, MD, MHCM, President and CEO of Jupiter Medical Center. “Our world-class caregivers consistently provide our patients with exceptional outcomes, and with our recent expansion news and UF Health partnership announcement, will soon be able to do even more. Our entire team of healthcare experts is unwavering in its commitment to providing the highest quality of care to our growing region.”

Earlier this year Jupiter Medical Center revealed plans for its new Surgical Institute. The 90,000-square-foot space is slated to open in 2023 with 16 state-of-the-art operating rooms and two hybrid rooms in a dedicated facility. Additionally, the independent, not-for-profit hospital system recently announced a partnership with UF Health to advance the organizations’ complementary missions of providing the best of academic and community medicine. Among other highlights, the partnership could also open up fast access to a large array of clinical trials.

For the 2022-2023 Best Hospitals rankings and ratings, U.S. News evaluated more than 4,500 hospitals across 15 specialties and 20 procedures and conditions.

“When patients are considering their options for care, the Best Hospitals ratings are designed to help them identify hospitals that excel in the kind of care they may need,” said Ben Harder, chief of health analysis and managing editor at U.S. News. “A hospital that’s earned a High Performing rating in a service may be a good option for patients in need of that service and their medical professionals to consider.”

The U.S. News Procedures & Conditions methodology is based entirely on objective measures of quality such as survival rates, patient experience, and how successfully each hospital helps patients get back home.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”